FDA takes action to boost third-party review programme
This article was originally published in Clinica
Executive Summary
The US FDA last week more than quadrupled the number of products eligible for review by outside experts to encourage greater participation in its third-party review programme. The agency announced in an updated guidance on the little-used programme that it was increasing the number of eligible third-party products from 154 to all 695 products allowed by law.